• Tadalafil-Primed MSC Exosomes Enhance PH Therapy via miR-29a

  2026-08-04

  A recent study demonstrates that pretreating mesenchymal stem cells with tadalafil significantly improves the therapeutic efficacy of their exosomes in pulmonary hypertension by upregulating miR-29a-3p. These findings suggest a promising strategy for enhancing exosome-based interventions targeting vascular inflammation and remodeling.

• Salvianolic Acid B Inhibits LH2 to Mitigate Pulmonary Fibros

  2026-08-04

  This study identifies Salvianolic acid B (Dan Shen Suan B) as a targeted inhibitor of lysyl hydroxylase 2 (LH2), disrupting pathological collagen cross-linking in pulmonary fibrosis. The findings elucidate its mechanism as an antifibrotic agent and support its application in extracellular matrix remodeling research.

• Metformin Hydrochloride in Immunometabolism: Protocols & Use

  2026-08-03

  Metformin Hydrochloride (Metformin HCl) is revolutionizing immunometabolism research as a precision AMPK pathway modulator, enabling reproducible dissection of glucose and lipid regulatory networks in immune responses. This article delivers actionable protocols, troubleshooting insights, and experimental innovations—bridging metabolic, immunological, and disease-focused studies using APExBIO’s trusted reagent.

• Salvianolic Acid B: Protocols and Workflows for Fibrosis Res

  2026-08-03

  Salvianolic acid B (Dan Shen Suan B) is a research-grade antifibrotic agent that enables precise inhibition of collagen cross-linking in pulmonary fibrosis models. This article details advanced workflows, protocol parameters, and troubleshooting strategies to maximize the reproducibility and translational value of Salvianolic acid B in extracellular matrix studies.

• Berberine Modulates SASP in Atherosclerosis via RXRα/PPARγ/N

  2026-08-02

  This study reveals that berberine suppresses senescence-associated secretory phenotype (SASP)-related inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 signaling cascade. The findings highlight a mechanistic link between berberine, macrophage-derived foam cell senescence, and chronic vascular inflammation, offering a foundation for targeted modulation of PPARγ pathways in cardiovascular research.

• Albiflorin Suppresses RCC Cell Growth via EGFR/MAPK Pathway

  2026-08-01

  This study integrates experimental and network pharmacology analyses to show that albiflorin, a natural bioactive compound, inhibits renal cell carcinoma (RCC) cell viability, proliferation, and migration. The findings highlight suppression of EGFR/MAPK signaling as a key mechanistic axis and underscore the value of combining computational and molecular approaches for target validation in oncology.

• NF-κB/Apaf1/Caspase-9 Axis Drives Tubular Injury in Septic A

  2026-07-31

  This study uncovers a sequential NF-κB/Apaf1/caspase-9/autophagy pathway that exacerbates tubular inflammation and apoptosis in septic acute kidney injury (AKI). By defining the mechanistic link between inflammatory signaling and impaired autophagy, the research highlights new opportunities for targeted intervention in sepsis-associated renal pathology.

• DeferoxamineB: Optimizing Iron Chelation in Regulated Cell D

  2026-07-31

  Deferoxamine (DeferoxamineB) empowers precision metabolic intervention in oncology by streamlining workflows for ferroptosis and cuproptosis assays. This guide translates new metabolic research into actionable protocols, troubleshooting strategies, and cross-domain applications for advanced cancer research.

• Sphingolipid Synthesis Inhibition Reduces Ferroptosis via HI

  2026-07-30

  Liu et al. reveal that pharmacological inhibition of sphingolipid synthesis by myriocin diminishes ferroptosis in neuronal cells by activating the HIF-1 pathway. This research identifies HIF1α stabilization as a key cytoprotective mechanism, suggesting a new direction for modulating regulated cell death in neurological disease models.

• Applied Use of (-)-Blebbistatin in Cytoskeletal and Cardiac

  2026-07-30

  (-)-Blebbistatin empowers precise, reversible inhibition of non-muscle myosin II, enabling high-fidelity dissection of actin-myosin interactions in cell mechanics and cardiac physiology. This article details experimental workflows, troubleshooting strategies, and the integration of temperature-sensitive cardiac assays, setting a new standard for cytoskeletal dynamics research.

• AM251: Potent CB1 Receptor Antagonist for Cannabinoid Resear

  2026-07-29

  AM251 is a high-affinity, selective CB1 receptor antagonist widely used in cannabinoid receptor research. Its well-characterized mechanism and reproducible effects on neurotransmitter release, apoptosis, and metabolic signaling make it a preferred tool for neuropharmacology and obesity treatment research.

• Annexin V-FITC/7-AAD Apoptosis Kit: Precision in Cell Death

  2026-07-29

  The Annexin V-FITC/7-AAD Apoptosis Kit offers rapid, dual-parameter assessment of apoptosis and necrosis, enabling clear discrimination of early and late cell death events. Its streamlined workflow and robust compatibility with flow cytometry make it indispensable for cytotoxicity and radiosensitization research.

• Cy5-UTP: Advanced RNA Labeling for FISH and Dual-Color Array

  2026-07-28

  Cy5-UTP (Cyanine 5-uridine triphosphate) empowers high-sensitivity, direct fluorescent RNA labeling for FISH, dual-color arrays, and in vitro transcription. Discover optimized workflows, experimental troubleshooting, and the latest innovations that set this APExBIO reagent apart for reliable, reproducible probe synthesis.

• U 46619: Advanced Insights into Platelet and Renal Vascular

  2026-07-28

  Explore the multifaceted applications of U 46619, a selective prostaglandin analogue, in platelet aggregation and renal vascular assays. This article reveals new scientific perspectives and protocol guidance for researchers using U 46619, with a focus on translational cardiovascular and renal research.

• Risedronate Sodium in Glucocorticoid Osteoporosis with RA: R

  2026-07-27

  The RISOTTO study provides the first high-quality evidence for the efficacy and safety of Risedronate Sodium in treating glucocorticoid-induced osteoporosis (GIO) among patients with rheumatoid arthritis. The trial demonstrates significant lumbar spine bone mineral density gains and a favorable safety profile, supporting its role as a targeted intervention in complex bone metabolism scenarios.

451 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page